M3, Inc. is a publicly traded company on the Tokyo Stock Exchange (JP:2413) with subsidiaries in major markets including USA, France, UK, Japan, S. Korea, and China, with over 2.5 million physician members globally via its physician websites. M3 Group provides services to the healthcare and life sciences industry, including market research, medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. For more information, please visit M3’s website.
Wake Research Associates
Wake Research is an organization of unified investigational sites working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device, pharmaceutical industry and clinical research organizations. Wake Research is fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications, leveraging a proprietary clinical database of nearly 1 million patients across its network. For more information, please visit Wake’s website.
Fort Washington, PA - Madison Park Group is pleased to announce that its client M3 USA, a group company of M3, Inc., a global leader in healthcare marketing, clinical trials, market research and physician recruitment services, has acquired Wake Research Associates, a clinical research site network. Madison Park Group served as exclusive buy-side advisor to M3 USA on the acquisition.
M3 USA CEO Aki Tomaru commented:
“Madison Park Group has been a trusted advisor to M3 on several acquisitions helping us navigate the complexities of each stage of the acquisition process. They did an outstanding job in driving a successful outcome in the acquisition of Wake.”
Jonathan Adler, Co-Founder and Managing Director at Madison Park Group, commented:
“Aki and the M3 team have built an extremely impressive business through a highly focused & strategic growth vision, and we are proud to have contributed to this vision over the course of seven acquisitions. The acquisition of Wake is particularly exciting as it marks M3’s entry into the clinical trial business in the U.S.”